Condition: Non-muscle Invasive Bladder Cancer With Carcinoma in Situ · Sponsor: Ferring Pharmaceuticals
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy will be evaluated in participants with NMIBC CIS (± high-grade Ta/T1).
This description comes directly from the study's public registry record.
Ferring Pharmaceuticals · 833-548-1402 (US/Canada) · disclosure@ferring.com
Ferring Pharmaceuticals · +1862-286-5200 (not US/Canada) · disclosure@ferring.com
Always discuss trial participation with your own doctor first.
| Center for Neurosciences | Tucson, Arizona, United States | Recruiting |
| Arkansas Urology, North Little Rock | Little Rock, Arkansas, United States | Recruiting |
| American Institute of Research | Los Angeles, California, United States | Recruiting |
| USC Kenneth Norris Jr Cancer Hospital | Los Angeles, California, United States | Recruiting |
| University of California, Irvine | Orange, California, United States | Recruiting |
| Genesis Research, LLC - San Diego | San Diego, California, United States | Recruiting |
| Advent Health | Denver, Colorado, United States | Recruiting |
| Colorado Urology - St. Anthony Hospital Campus | Lakewood, Colorado, United States | Recruiting |
| Yale School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Medstar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Sarasota Memorial Healthcare System | Sarasota, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
+ 64 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06545955